Kao Corporation
Search results
Welcome to the official website of Taisho Pharmaceutical Holdings, the holding company for the Taisho Pharmaceutical Group. We aim to contribute to healthier living for all while raising the enterprise value of the Group as a whole.
With over a century of history, Taisho Pharmaceutical Holdings has the largest share of Japan’s over-the-counter pharmaceutical market and a strong presence in health food, cosmetics, and other fields.
Taisho Pharmaceutical Co., Ltd. (大正製薬株式会社, Taishō Seiyaku Kabushiki-gaisha), commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo. [3] History [ edit ]
Get a quick overview of Taisho Pharmaceutical Holdings, including our history and best-selling products.
HOE Pharmaceuticals Sdn Bhd is a subsidiary company of Taisho Pharmaceutical Group in Malaysia, TAISHO a Japanese MNC focused on the development, manufacturing and marketing of two broad product categories – prescription pharmaceutical and self-medication.
Gets You Going! | Taisho Pharmaceutical Malaysia is a subsidiary company of TAISHO Pharmaceutical Co., Ltd. Japanese MNC focused on the manufacturing of Energy Drink known as Lipovitan/...
Stop. We are driven by the passion to nurture and preserve the precious moments of everyday life for all people, regardless of their health condition. From treatment to disease prevention, we will continue to develop innovative new drugs that contribute to better health and bring smiles to the faces of people everywhere.
Considering a career at Taisho Pharmaceutical Indonesia? Learn what its like to work for Taisho Pharmaceutical Indonesia by reading employee ratings and reviews on jobstreet.com.my
Feb 5, 2024 · Taisho Pharmaceutical (M) Sdn. Bhd. is based in Malaysia, with the head office in Petaling Jaya. The company operates in the Pharmacies and Drug Stores sector. It was first established on September 22, 1990. The company’s latest financial report indicates a net sales revenue drop of 2.15% in 2022.
Dec 6, 2023 · Japan’s Taisho Pharmaceutical looks like it could be heading into private ownership, thanks to a management buyout offer (MBO) that could value the company at almost $5 billion.
